Evaluation of clinical benefit from treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis

BACKGROUND: In a recent phase III trial (NCT02020889), 53% of mepolizumab-treated, versus 19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) achieved protocol-defined remission. OBJECTIVE: To investigate post hoc the clinical benefit of mepolizumab in patients...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Allergy Clin Immunol
Autores principales: Steinfeld, Jonathan, Bradford, Eric S., Brown, Judith, Mallett, Stephen, Yancey, Steven W., Akuthota, Praveen, Cid, Maria C., Gleich, Gerald J., Jayne, David, Khoury, Paneez, Langford, Carol A, Merkel, Peter A., Moosig, Frank, Specks, Ulrich, Weller, Peter F., Wechsler, Michael E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7254609/
https://ncbi.nlm.nih.gov/pubmed/30578883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2018.11.041
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares